New combo therapy aims to shrink lung tumors before surgery
NCT ID NCT07264647
First seen Dec 16, 2025 · Last updated May 14, 2026 · Updated 21 times
Summary
This study tests a combination of chemotherapy and immunotherapy (tislelizumab) given before surgery for people with stage III non-small cell lung cancer that is PD-L1 positive. The goal is to see if this approach helps more patients have successful surgery to remove all cancer. About 30 adults who are current or former smokers and have not had prior treatment will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Istituti Fisioterapici Ospitalieri
RECRUITINGRome, Roma (RM), 00144, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.